Heroes and pillars of rheumatology

1625 EULAR 75-year anniversary: commentaries on ARD papers from 25 years ago
K I Hyrich

Recommendations

1628 EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

Spondyloarthitis

1678 Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis
T S H Kwock, M Sutton, D Pereira, R J Cook, V Chandran, N Haroon, R D Inman, D Gladman

Systemic lupus erythematosus

1685 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
J Y Humrich, P Cacoulis, M Rosenzweig, F Piozier, H P PHAM, J Gaudoux, D Leroux, T Vazquez, G Iemekasten, J S Smolen, G Tsokos, D Klatzmann

1695 Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α

Rheumatoid arthritis

1661 Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

1669 Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis
M Cheng, Y Zhao, Y Cui, C Zheng, Y Zha, S Li, G Cao, M Li, L Zhang, Q Ning, J Han

Contents

Volume 81 Issue 12 | ARD December 2022

Editor
J osef S Smolen

Associate Editors
Francis Berenbaum
Dimitris Bourmas
Mary Crow
Kimmi Hyrich
Rik Laurens
Ian McNiven
Caroline Dippele
Thomas Papi
David Pietzsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK

T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ

ISSN: 0001-6496 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeSet by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases; ISSN: 0001-6496 (UPSP: 2151) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Artwork and mailing in the USA by agent named World Container Inc, 150-15, 163rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 163rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (http://publicationethics.org/).

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See http://authors.bmj.com/open-access/access

Address correspondence to: Désirée van der Heijde.

http://ard.bmj.com/

November 29, 2022

Downloaded from

Published online on 1 December 2022.
Systemic sclerosis

1722 Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSICS-ON
Y Allarese, M C Vonk, O Distler, A Azuma, M D Mayes, M Stockmann, A James, V Kohlbrenner, M Alves, D Khanna, K B Highland, on behalf of the SENSICS-ON trial investigators

Autoinflammatory disorders

1730 Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoinimmune polyarthrits induced by therapy with immune checkpoint inhibitors

Epidemiology

1742 Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave
Y Kawano, N J Patzel, X Wang, C E Cook, K MM Vani, E N Kowalski, E P Banasik, G Qian, M Diloro, T Y-T Hsu, M W Eimblatt, D J Todd, Z S Wallace, J A Sparks

1750 Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

1757 Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

eular news

1767 News from EULAR
EULAR Communications

Letters

1768 Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink
A Abhishek, E Cipolletta, G Nakafo, A D Avery, M Mamas, L J Tata

1769 Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
A Bettiol, M L Urban, F Bello, D Fiori, I Mattioli, G Lozupone, I A Buan, I Dagna, M Caminati, S Negroti, E Barzaghi, M Focci, F Franceschini, R Padovan, O Fassmann, R Solans, J Schroeder, M André, L Mi, P Parrotchi, D Roccella, S Szász, D Jayne, D Prisco, A Vazquez, G Emmi, on behalf of the European EGPA Study Group

Electronic pages

e239 Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’
M J Ventura, E Casado, E H Clark, K Bhanavasata, R Y Kherallah, A R DiNardo, N Ye, P A Piedoa, R L Atmar, S K Agarwal

e240 Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Ventura et al’

e241 Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’
Correspondence on 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases' by Wu et al
J L Pablos, M Calindo, R Blanco, J M Alvarez-Gracia

No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
P Aries, C Ieong-Konert

Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'
C Xu

Response to: 'Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'' by Xu
C C Alok

Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'
Z Zhou, F Wang, Y Sun, J Feng, H Liu, X Cheng, Y Su, H Shi, Y You, C Yang, J Ye

Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'' by Zhou et al
M G Tektonidou, A Tincani, M M Ward

Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'
M Bredemeier

Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier
J R Seifhold, V Kohlbrenner, M Alves, O Distler

Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'
Z T Zhang, W Huang, C-H Lu, J Li, M-X Zuo, Z-H Dai

Response to: 'Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'' by Zhang et al
B S Koo, J S Oh, S Y park, J H Shin, G Y Ahn, S Lee, K B Joo, T H Kim

Correspondence on 'Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression'
L-T Wzio, K S-K Ma

Response to: 'Correspondence on 'Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression'' by Wang and Ma
A Watad, C Bridgewood, D G McGonagle

Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'
H Satag, E Aydemir, K Izmirlioğlu, A Tufan

Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al
S Ozen, F De Benedetti

Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'
H Wang, L Niu

Response to: 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu
P He, H Zhu, L-F Wu, F-Y Deng, S-F Lei

Role of interaction between B cells and epithelial cells in pSS
S Pringle, G M Versappelen, H Botsma, F G M Kroese

Response to: 'Role of interaction between B cells and epithelial cells in pSS'' by Pringle et al
E Rivière, X Mariette, G Nocturne

Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
R Watanabe, M Hashimoto

Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
K S M van der Geest, M Sandovici, A Rutgers, T J N Hulsmann, S F Oosting, R H J A Slot, E Brouwer